Amgen Inc. is facing a significant drop in its stock price, raising concerns among investors about its future performance.
Amgen Inc. (NASDAQ:AMGN) saw its stock price decrease by 1.13% today, closing at CA$412.84. This decline occurs in a challenging environment for the pharmaceutical giant, which is dealing with increasing competition and pressures from recent market developments.
Investor takeaway: Investors should keep a close eye on Amgen's performance and consider the implications of its current challenges, especially in light of recent news affecting the pharmaceutical industry.
Advertisement
Amgen Inc
AMGN.US
AMGN.US
Amgen Inc
WealthAwesomeMarket cap
$224.29B
P/E
25.8x
Div. yield
2.41%
Div. / share
$9.80
52W high
$447.03
52W low
$280.23
1W change
+3.62%
Beta
0.41
Analyst Price Targets
Based on 34 analysts covering AMGN · as of Oct 12, 2026
Wall Street analysts forecast AMGN stock price to fall 5.3% over the next 12 months.
Consensus
Hold3.35 / 5.00
Avg. Target
C$395.25
-5.3% Upside
Previously C$391.46 on Oct 9, 2026
Current Price
C$417.57
Last close
Analyst Breakdown (34 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AMGN's historical volatility
30-Day Vol
40.5%
Annualized
90-Day Vol
32.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$499.21
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$443.18 | C$385.34 – C$509.70 |
| 60 trading days | C$470.36 | C$385.96 – C$573.22 |
| 90 trading days | C$499.21 | C$391.82 – C$636.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Amgen has a promising pipeline of innovative drugs, including its KRAS inhibitor LUMAKRAS, which could drive future growth and help offset current weaknesses.
Bear case
The recent performance of Amgen's stock reflects broader concerns about its ability to sustain growth amid increasing competition and the decline of its legacy products.
Market Pressures Impacting Amgen
Today's drop in Amgen's stock can be linked to a broader market sentiment affecting pharmaceutical companies. Recent earnings reports from competitors, such as Johnson & Johnson, have revealed challenges in the sector, including missed sales estimates and rising operational costs. This environment raises questions about Amgen's ability to maintain its growth trajectory.
Advertisement
Competition and Pipeline Challenges
Amgen faces significant competition from both established players and emerging biotech firms. The recent launch of biosimilars for its key products, including Stelara, has put pressure on its revenue streams. Investors are particularly concerned about the long-term sustainability of Amgen's legacy products, which are seeing declining sales.
Looking Ahead: What Investors Should Consider
As Amgen navigates these challenges, investors should monitor its pipeline developments and market positioning. The success of new drugs like LUMAKRAS could be crucial in offsetting current weaknesses. However, the overall sentiment in the pharmaceutical sector remains cautious, and investors may want to reassess their exposure to Amgen in light of these dynamics.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
